AOD-9604 vs Retatrutide
Both AOD-9604 and Retatrutide are used for weight-loss. Here's how their evidence, dosing, and regulatory status actually compare.
AOD-9604
Evidence C+Anti-Obesity Drug 9604
A modified fragment of human growth hormone (hGH 176-191) that stimulates fat breakdown without the growth-promoting or diabetogenic effects of full HGH.
View full AOD-9604 profile →Retatrutide
Evidence ARetatrutide (LY3437943)
Triple agonist at GLP-1, GIP, and glucagon receptors. Phase 2 produced 24.2% mean weight reduction at 48 weeks — the highest ever in a clinical obesity trial.
View full Retatrutide profile →Side-by-Side
| Attribute | AOD-9604 | Retatrutide |
|---|---|---|
| Evidence Grade | C+ | A |
| FDA Status | Not FDA-approved — Category 1 (compounding allowed) | Not FDA-approved — Phase 3 trials (TRIUMPH program) for obesity |
| Typical Dose | 250–500 mcg daily (subcutaneous) | Trial range: 1–12 mg weekly (subcutaneous) |
| Clinics Indexed | 134 | 12 |
| Categories | weight-loss, fat-loss | weight-loss, metabolic |
Key reported benefits — AOD-9604
- ✓Fat metabolism
- ✓No HGH side effects
- ✓Cartilage repair potential
Key reported benefits — Retatrutide
- ✓Highest reported weight loss
- ✓Triple incretin/glucagon mechanism
- ✓Metabolic improvement
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.